Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

PRECISION TOXICOLOGY, LLC

NPI: 1871907915 · MARQUETTE, MI 49855 · Clinical Medical Laboratory · NPI assigned 06/17/2014

$758K
Total Medicaid Paid
10,987
Total Claims
7,284
Beneficiaries
5
Codes Billed
2018-01
First Month
2022-08
Last Month

Provider Details

Authorized OfficialGALLEGO, MIGUEL (CEO)
Parent OrganizationPRECISION TOXICOLOGY
NPI Enumeration Date06/17/2014

Related Entities

Other providers sharing the same authorized official: GALLEGO, MIGUEL

ProviderCityStateTotal Paid
PRECISION TOXICOLOGY, LLC SAN DIEGO CA $213.77M
PRECISION TOXICOLOGY, LLC DARTMOUTH MA $3.19M
PRECISION TOXICOLOGY, LLC WEST HARTFORD CT $2.93M

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2018 342 $36K
2019 2,034 $148K
2020 2,407 $159K
2021 3,637 $236K
2022 2,567 $179K

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed 6,265 3,899 $591K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 4,172 2,904 $120K
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed 155 147 $25K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 370 309 $19K
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed 25 25 $3K